FTSE 100 news / Companies and sectors / AstraZeneca / 9 October 2026
AstraZeneca (AZN): news on Friday 9 October 2026
+7.0 strongly positive
Coverage was mostly positive, led by EU approvals for Trixeo in asthma and a camizestrant companion diagnostic, a China approval for a breast cancer drug, and a Jefferies Buy rating. The completed $2B Summit investment and a rally in the shares added support, while merger speculation was a minor drag.
What drove it
- regulatory approvals
- Summit investment
- analyst Buy rating
The 15 stories
- +9.2 AstraZeneca’s Trixeo approved in EU for asthma
EU approval of Trixeo for asthma widens its use - +9.2 Astrazeneca, Daiichi Sankyo's Breast Cancer Drug Approved in China
China approval of breast cancer drug with Daiichi Sankyo - +9.2 Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer
EU companion diagnostic approval supports camizestrant launch in Europe - +8.3 Jefferies keeps Buy rating for AstraZeneca stock at GBp 17,500
Jefferies maintains Buy with high price target - +7.5 AstraZeneca (AZN) Seeks FDA Approval for New Lung Cancer Treatment. Can It Fuel Oncology Growth?
FDA filing for new lung cancer treatment supports oncology growth - +6.7 AZN rallies as Summit Therapeutics investment completes
Shares rallied as Summit investment completed - +5.8 AstraZeneca Executes $2B Summit Investment to Advance Bispecific ADC Cancer Combos
$2B Summit investment to advance bispecific ADC combinations - +5.0 Myriad, SOPHiA GENETICS and AstraZeneca team up on prostate cancer genomic score PrGIS
Collaboration on prostate cancer genomic score with AstraZeneca - +5.0 Myriad Genetics (MYGN) Partners with AstraZeneca and SOPHiA Gene
Diagnostic partnership involving AstraZeneca in prostate cancer - +5.0 Myriad, SOPHiA partner with AstraZeneca to use prostate cancer technology
Partnership on prostate cancer technology - −3.3 Is merger speculation still weighing on AstraZeneca (LSE:AZN) shares this week?
Merger speculation said to be weighing on shares - +3.3 AstraZeneca’s Kazakhstan Breast Cancer Study: Real‑World Data With Quiet but Important Signals for AZN
Real-world breast cancer data, modestly supportive - +3.3 AstraZeneca’s Liver Cancer Trial Completion: What It Means for AZN Investors
Liver cancer trial completion, routine pipeline progress - +1.7 AstraZeneca vs GSK: Comparing Two UK Stocks in AI-Driven Healthcare
Stock comparison with GSK, mildly positive framing - +0.8 Scientists Behind AstraZeneca COVID Jab Rush to Develop Plague Vaccine as Pandemic Fears Grow
Clickbait-style piece on COVID jab scientists; tenuous link to company
AstraZeneca: every day · Pharma and healthcare on 9 October 2026 · FTSE 100 overview for the day